Atlas Trials

Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes

Clinical trial NCT02461589 · COMPLETED

Trial details

NCT number
NCT02461589
Sponsor
Novo Nordisk A/S
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
DiabetesDiabetes Mellitus, Type 2
Start date
2015-09-21
Primary completion
2016-10-13
Enrollment
706

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.